Key result
Preexisting diabetes mellitus was significantly associated with an increased risk of developing chemotherapy-induced peripheral neuropathy in cancer patients (OR 1.60).
Why the study?
Does diabetes mellitus increase the risk of chemotherapy-induced peripheral neuropathy in cancer patients?
Meta-Analysis (n=8,923)
Does diabetes mellitus increase the risk of chemotherapy-induced peripheral neuropathy in cancer patients?
Diabetes mellitus is a significant risk factor for the development of chemotherapy-induced peripheral neuropathy in cancer patients.
May warrant closer CIPN monitoring in diabetic patients on chemotherapy; supports diabetes as a CIPN risk factor.
BACKGROUND: To identify the association between diabetes mellitus (DM) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) through a systematic review and meta-analysis. METHODS: An electronic literature search was conducted in PubMed, Embase, Web of Science, the Wanfang database, the VIP Journals database (CQVIP), the China National Knowledge Infrastructure (CNKI) database, and the China Biology Medicine database (Sinomed) between January 2010 and January 2021. Articles were included if they investigated CIPN and DM. Stata 15.1 was used to analyze the data. RESULTS: We examined 8923 cancer patients from 25 studies comprising 9 cohort studies and 16 case-control studies. Meta-analysis showed that there was a statistically significant positive correlation between DM and CIPN (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.38-1.85, P < 0.001). Egger's test (P = 0.824) showed no evidence of publication bias. The positive associations did not significant differ by study type, study quality, evaluation instrument, and type of antineoplastic drug. Omission of any single study had little effect on the combined risk estimate. Little evidence of heterogeneity was observed. CONCLUSION: This meta-analysis provides evidence of a significant positive association between DM and risk of CIPN. Furthermore, a more detailed evaluation is warranted for cancer patients with diabetes when they are treated with antineoplastic drugs that have the potential to cause peripheral neuropathy.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2021) conducted a meta-analysis in Chemotherapy-induced peripheral neuropathy (CIPN) (n=8,923). Diabetes mellitus vs. Non-diabetic patients was evaluated on Incidence of chemotherapy-induced peripheral neuropathy (CIPN) (OR 1.60, 95% CI 1.38-1.85, p=<0.001). Preexisting diabetes mellitus was significantly associated with an increased risk of developing chemotherapy-induced peripheral neuropathy in cancer patients (OR 1.60).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: